TY - JOUR T1 - Sex-specific transcriptional differences and loss of gene imprinting in pancreatic neuroendocrine tumors JF - medRxiv DO - 10.1101/2021.06.09.21258573 SP - 2021.06.09.21258573 AU - Nikolay A. Ivanov AU - Kirill Grigorev AU - Thomas J. Fahey III AU - Brendan M. Finnerty AU - Christopher E. Mason AU - Irene M. Min Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/15/2021.06.09.21258573.abstract N2 - Pancreatic neuroendocrine tumors (PNETs) occur more frequently in men and are associated with higher mortality in males; however, the molecular basis for these sexual dimorphisms is unclear. Here, we demonstrate that PNETs are associated with the emergence of unique sex-specific transcriptomic differences that are not observed in non-neoplastic pancreatic islet tissues. We also show that while widespread sex-specific differences are present in the DNA methylation landscapes of control pancreatic islets, they are erased in PNETs. This includes a loss of imprinting with regards to many genes. These results implicate an emergence of sex-associated genetic and epigenetic dysregulations in PNETs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR002386-04 (NAI) and North American Neuroendocrine Tumor Society (NANTS 190177; to IMM). It is also supported by the STARR Consortium (I13-0052), the NIH (R01MH117406, P01CA214274, R01CA249054, R01MH117406), and the Leukemia and Lymphoma Society (LLS) grants (LLS Grant: MCL7001-18, LLS 9238-16, LLS-MCL7001-18) (CEM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was obtained from the Weill Cornell Medicine Institutional Regulatory Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProcessed RNA sequencing data (log2(TPM+1) values) for all samples sequenced in this study are provided as Supplementary Data 1. ER -